Payment overview · 2025
General Payments
$2,295.55
90 reported records · 16 companies
Healthcare provider profile · identity verified
Luis C Quintero, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · CORAL GABLES, FL · NPI 1710073648
Verified facts
What the public records show
CMS Open Payments records show Luis C Quintero, MD received $2,295.55 in general payments during 2025 across 90 reported records.
Insulet Corporation accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 500 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insulet Corporation | Unresolved — no canonical attribution shown | $726.11 | 31.6% | 34 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $388.73 | 16.9% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $208.71 | 9.1% | 9 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $170.67 | 7.4% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$165.40 | 7.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $133.96 | 5.8% | 7 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $110.23 | 4.8% | 5 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $90.67 | 4.0% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $76.64 | 3.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $67.96 | 3.0% | 3 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $39.95 | 1.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $29.45 | 1.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.97 | 1.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.27 | 1.0% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $20.70 | 0.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.13 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,244.51 | 89 |
| Travel and Lodging | $51.04 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $726.11 | 34 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $388.73 | 15 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $182.82 | 8 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $170.67 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $93.32 | 4 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $90.67 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $86.87 | 4 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $76.64 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $62.91 | 4 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $49.94 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.06 | 3 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $39.95 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $29.45 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| MYCARELINK Normalized: mycarelink |
Device | Medtronic, Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $3.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 120 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 142 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 500 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
114 | 31 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 30 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
142 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
151 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
500 | 95 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 500 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 397 | 118 |
| Metformin Hcl | Metformin Hcl | 357 | 106 |
| Trulicity | Dulaglutide | 151 | 30 |
| Mounjaro | Tirzepatide | 142 | 35 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 125 | 40 |
| Jardiance | Empagliflozin | 120 | 30 |
| Farxiga | Dapagliflozin Propanediol | 116 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 115 | 42 |
| Synthroid | Levothyroxine Sodium | 114 | 31 |
| Humalog Kwikpen U-100 | Insulin Lispro | 102 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 36 |
| Glimepiride | Glimepiride | 88 | 28 |
| Januvia | Sitagliptin Phosphate | 87 | 21 |
| Tresiba Flextouch U-100 | Insulin Degludec | 87 | 19 |
| Atorvastatin Calcium | Atorvastatin Calcium | 77 | 24 |
| Humalog | Insulin Lispro | 60 | 17 |
| Glyxambi | Empagliflozin/Linagliptin | 58 | suppressed |
| Methimazole | Methimazole | 58 | 17 |
| Novolog Flexpen | Insulin Aspart | 57 | 22 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 51 | 20 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 50 | 21 |
| Tradjenta | Linagliptin | 48 | 19 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Losartan Potassium | Losartan Potassium | 45 | 19 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 45 | 12 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 45 | 11 |
| Gabapentin | Gabapentin | 43 | 17 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 39 | 13 |
| Nateglinide | Nateglinide | 38 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 35 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 35 | suppressed |
| Glipizide | Glipizide | 34 | 11 |
| Humalog Kwikpen U-200 | Insulin Lispro | 34 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 12 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 33 | 11 |
| Simvastatin | Simvastatin | 32 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | suppressed |
| Lisinopril | Lisinopril | 30 | 13 |
| Azithromycin | Azithromycin | 28 | 23 |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 27 | suppressed |
| Omeprazole | Omeprazole | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Furosemide | Furosemide | 24 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 23 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Humulin R | Insulin Regular, Human | 17 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Cabergoline | Cabergoline | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 15 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,295.55 · 90 records | Insulet Corporation | CREON, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, Korlym, LEQVIO, LINZESS, MOUNJARO, MYCARELINK, NUPLAZID, Omnipod, Ozempic, RECORLEV, REPATHA, REZDIFFRA, Rybelsus, TEPEZZA, TWIIST, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error